Improving the safety of T-Cell therapies using an inducible caspase-9 gene

Experimental Hematology

Volumn 44, Issue 11, 2016, Pages 1013-1019

  Zhou, Xiaoou ^a   Brenner, Malcolm K ^a  

^a TEXAS CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; CASPASE 9; CD20 ANTIGEN; CD34 ANTIGEN; CYTOSINE DEAMINASE; EPIDERMAL GROWTH FACTOR RECEPTOR; FK 506 BINDING PROTEIN; FLUCYTOSINE; FLUOROURACIL; GANCICLOVIR; INTERLEUKIN 2 RECEPTOR ALPHA; RIMIDUCID; RITUXIMAB; MONOCLONAL ANTIBODY; PRODRUG;

ACUTE GRAFT VERSUS HOST DISEASE; ADOPTIVE TRANSFER; ANTIGEN SPECIFICITY; APOPTOSIS; B CELL LYMPHOMA; CANCER IMMUNOTHERAPY; CELL ACTIVATION; CELL ENGINEERING; CELL EXPANSION; CELL THERAPY; CLINICAL EFFECTIVENESS; CYTOMEGALOVIRUS INFECTION; DIMERIZATION; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOGENICITY; LYMPHOCYTE FUNCTION; NONHODGKIN LYMPHOMA; NONHUMAN; PANCYTOPENIA; PHENOTYPE; PRIORITY JOURNAL; REVIEW; SAFETY; SUICIDE GENE; T LYMPHOCYTE; ADOPTIVE IMMUNOTHERAPY; ADVERSE EFFECTS; ANIMAL; BIOLOGICAL THERAPY; CELL TRANSPLANTATION; CHEMISTRY; DONOR; GENE EXPRESSION REGULATION; GENE THERAPY; GENETIC ENGINEERING; GENETICS; GRAFT VS HOST DISEASE; IMMUNOLOGY; LYMPHOCYTE DEPLETION; METABOLISM; PROCEDURES; PROTEIN MULTIMERIZATION; SUICIDE TRANSGENE; TRANSPLANTATION;

ANIMALS; ANTIBODIES, MONOCLONAL; CASPASE 9; CELL ENGINEERING; CELL TRANSPLANTATION; CELL- AND TISSUE-BASED THERAPY; GENE EXPRESSION REGULATION; GENES, TRANSGENIC, SUICIDE; GENETIC ENGINEERING; GENETIC THERAPY; GRAFT VS HOST DISEASE; HUMANS; IMMUNOTHERAPY, ADOPTIVE; LYMPHOCYTE DEPLETION; PRODRUGS; PROTEIN MULTIMERIZATION; T-LYMPHOCYTES; TISSUE DONORS;

EID: 84992630807     PISSN: 0301472X     EISSN: 18732399     Source Type: Journal    
DOI: 10.1016/j.exphem.2016.07.011     Document Type: Review

References (82)

1. 1 Walter, E.A., Greenberg, P.D., Gilbert, M.J., et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med 333 (1995), 1038–1044.
2. 2 Rooney, C.M., Smith, C.A., Ng, C.Y., et al. Infusion of cytotoxic T cells for the prevention and treatment of Epstein–Barr virus-induced lymphoma in allogeneic transplant recipients. Blood 92 (1998), 1549–1555.
3. 3 Dudley, M.E., Wunderlich, J.R., Robbins, P.F., et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298 (2002), 850–854.
4. 4 Gottschalk, S., Rooney, C.M., Adoptive T-cell immunotherapy. Curr Top Microbiol Immunol 391 (2015), 427–454.
5. 5 Heslop, H.E., Slobod, K.S., Pule, M.A., et al. Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood 115 (2010), 925–935.
6. 6 Savoldo, B., Ramos, C.A., Liu, E., et al. CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. J Clin Invest 121 (2011), 1822–1826.
7. 7 Xu, Y., Zhang, M., Ramos, C.A., et al. Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15. Blood 123 (2014), 3750–3759.
8. 8 Melenhorst, J.J., Castillo, P., Hanley, P.J., et al. Graft versus leukemia response without graft-versus-host disease elicited by adoptively transferred multivirus-specific T-cells. Mol Ther 23 (2015), 179–183.
9. 9 Louis, C.U., Savoldo, B., Dotti, G., et al. Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. Blood 118 (2011), 6050–6056.
10. 10 Bollard, C.M., Gottschalk, S., Torrano, V., et al. Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein–Barr virus latent membrane proteins. J Clin Oncol 32 (2014), 798–808.
11. 11 Porter, D.L., Levine, B.L., Kalos, M., et al. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 365 (2011), 725–733.
12. 12 Maude, S.L., Frey, N., Shaw, P.A., et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med 371 (2014), 1507–1517.
13. 13 Garfall, A.L., Maus, M.V., Hwang, W.T., et al. Chimeric antigen receptor T cells against CD19 for multiple myeloma. N Engl J Med 373 (2015), 1040–1047.
14. 14 Ahmed, N., Brawley, V.S., Hegde, M., et al. Human epidermal growth factor receptor 2 (HER2)-specific chimeric antigen receptor-modified T cells for the immunotherapy of HER2-positive sarcoma. J Clin Oncol 33 (2015), 1688–1696.
15. 15 Cruz, C.R., Micklethwaite, K.P., Savoldo, B., et al. Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: A phase 1 study. Blood 122 (2013), 2965–2973.
16. 16 Morgan, R.A., Yang, J.C., Kitano, M., et al. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing erbb2. Mol Ther 18 (2010), 843–851.
17. 17 Kochenderfer, J.N., Dudley, M.E., Feldman, S.A., et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood 119 (2012), 2709–2720.
18. 18 Brentjens, R.J., Riviere, I., Park, J.H., et al. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood 118 (2011), 4817–4828.
19. 19 Linette, G.P., Stadtmauer, E.A., Maus, M.V., et al. Cardiovascular toxicity and Titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. Blood 122 (2013), 863–871.
20. 20 Cameron, B.J., Gerry, A.B., Dukes, J., et al. Identification of a Titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cells. Sci Transl Med, 5, 2013, 197ra103.
21. 21 Kalos, M., Levine, B.L., Porter, D.L., et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med, 3, 2011, 95ra73.
22. 22 Grupp, S.A., Kalos, M., Barrett, D., et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med 368 (2013), 1509–1518.
23. 23 Lee, D.W., Kochenderfer, J.N., Stetler-Stevenson, M., et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: A phase 1 dose-escalation trial. Lancet 385 (2015), 517–528.
24. 24 Teachey, D.T., Lacey, S.F., Shaw, P.A., et al. Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T cell therapy for acute lymphoblastic leukemia. Cancer Discov 6 (2016), 664–679.
25. 25 Brentjens, R.J., Davila, M.L., Riviere, I., et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med, 5, 2013, 177ra138.
26. 26 Kochenderfer, J.N., Wilson, W.H., Janik, J.E., et al. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood 116 (2010), 4099–4102.
27. 27 Davila, M.L., Riviere, I., Wang, X., et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med, 6, 2014, 224ra225.
28. 28 Fedorov, V.D., Themeli, M., Sadelain, M., PD-1- and CTLA-4-based inhibitory chimeric antigen receptors (iCARs) divert off-target immunotherapy responses. Sci Transl Med, 5, 2013, 215ra172.
29. 29 Zhao, Y., Moon, E., Carpenito, C., Paulos, C.M., Liu, X., Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor. Cancer Res 70 (2010), 9053–9061.
30. 30 Maus, M.V., Haas, A.R., Beatty, G.L., et al. T cells expressing chimeric antigen receptors can cause anaphylaxis in humans. Cancer Immunol Res 1 (2013), 26–31.
31. 31 Beatty, G.L., Haas, A.R., Maus, M.V., et al. Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies. Cancer Immunol Res 2 (2014), 112–120.
32. 32 Serafini, M., Manganini, M., Borleri, G., et al. Characterization of CD20-transduced T lymphocytes as an alternative suicide gene therapy approach for the treatment of graft-versus-host disease. Hum Gene Ther 15 (2004), 63–76.
33. 33 Griffioen, M., van Egmond, E.H., Kester, M.G., Willemze, R., Falkenburg, J.H., Heemskerk, M.H., Retroviral transfer of human CD20 as a suicide gene for adoptive T-cell therapy. Haematologica 94 (2009), 1316–1320.
34. 34 Introna, M., Barbui, A.M., Bambacioni, F., et al. Genetic modification of human T cells with CD20: A strategy to purify and lyse transduced cells with anti-CD20 antibodies. Hum Gene Ther 11 (2000), 611–620.
35. 35 Philip, B., Kokalaki, E., Mekkaoui, L., et al. A highly compact epitope-based marker/suicide gene for easier and safer T-cell therapy. Blood 124 (2014), 1277–1287.
36. 36 Wang, X., Chang, W.C., Wong, C.W., et al. A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells. Blood 118 (2011), 1255–1263.
37. 37 Jensen, M.C., Riddell, S.R., Designing chimeric antigen receptors to effectively and safely target tumors. Curr Opin Immunol 33 (2015), 9–15.
38. 38 Bonini, C., Ferrari, G., Verzeletti, S., et al. HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. Science 276 (1997), 1719–1724.
39. 39 Tiberghien, P., Ferrand, C., Lioure, B., et al. Administration of herpes simplex-thymidine kinase-expressing donor T cells with a T-cell-depleted allogeneic marrow graft. Blood 97 (2001), 63–72.
40. 40 Haack, K., Moebius, U., Knebel Doeberitz, M.V., et al. Detection of cytosine deaminase in genetically modified tumor cells by specific antibodies. Hum Gene Ther 8 (1997), 1395–1401.
41. 41 Tiraby, M., Cazaux, C., Baron, M., Drocourt, D., Reynes, J.P., Tiraby, G., Concomitant expression of E. coli cytosine deaminase and uracil phosphoribosyltransferase improves the cytotoxicity of 5-fluorocytosine. FEMS Microbiol Lett 167 (1998), 41–49.
42. 42 Kievit, E., Bershad, E., Ng, E., et al. Superiority of yeast over bacterial cytosine deaminase for enzyme/prodrug gene therapy in colon cancer xenografts. Cancer Res 59 (1999), 1417–1421.
43. 43 Pandha, H.S., Martin, L.A., Rigg, A., et al. Genetic prodrug activation therapy for breast cancer: A phase I clinical trial of erbB-2-directed suicide gene expression. J Clin Oncol 17 (1999), 2180–2189.
44. 44 Raza, A., Kohila, V., Ghosh, S.S., Redesigned Escherichia coli cytosine deaminase: A new facet of suicide gene therapy. J Gene Med 17 (2015), 132–139.
45. 45 Rodgers, D.T., Mazagova, M., Hampton, E.N., et al. Switch-mediated activation and retargeting of CAR-T cells for B-cell malignancies. Proc Natl Acad Sci USA 113 (2016), E459–E468.
46. 46 Ballen, K.K., Koreth, J., Chen, Y.B., Dey, B.R., Spitzer, T.R., Selection of optimal alternative graft source: Mismatched unrelated donor, umbilical cord blood, or haploidentical transplant. Blood 119 (2012), 1972–1980.
47. 47 Palma, J., Salas, L., Carrión, F., et al. Haploidentical stem cell transplantation for children with high-risk leukemia. Pediatr Blood Cancer 59 (2012), 895–901.
48. 48 Aversa, F., Terenzi, A., Tabilio, A., et al. Full haplotype-mismatched hematopoietic stem-cell transplantation: A phase II study in patients with acute leukemia at high risk of relapse. J Clin Oncol 23 (2005), 3447–3454.
49. 49 Bethge, W.A., Haegele, M., Faul, C., et al. Haploidentical allogeneic hematopoietic cell transplantation in adults with reduced-intensity conditioning and CD3/CD19 depletion: Fast engraftment and low toxicity. Exp Hematol 34 (2006), 1746–1752.
50. 50 Andre-Schmutz, I., Le Deist, F., Hacein-Bey-Abina, S., et al. Immune reconstitution without graft-versus-host disease after haemopoietic stem-cell transplantation: A phase 1/2 study. Lancet 360 (2002), 130–137.
51. 51 Amrolia, P.J., Muccioli-Casadei, G., Yvon, E., et al. Selective depletion of donor alloreactive T cells without loss of antiviral or anti-leukemic responses. Blood 102 (2003), 2292–2299.
52. 52 Amrolia, P.J., Muccioli-Casadei, G., Huls, H., et al. Adoptive immunotherapy with allodepleted donor T-cells improves immune reconstitution after haploidentical stem cell transplantation. Blood 108 (2006), 1797–1808.
53. 53 Perruccio, K., Tosti, A., Burchielli, E., et al. Transferring functional immune responses to pathogens after haploidentical hematopoietic transplantation. Blood 106 (2005), 4397–4406.
54. 54 Leen, A.M., Christin, A., Myers, G.D., et al. Cytotoxic T lymphocyte therapy with donor T cells prevents and treats adenovirus and Epstein–Barr virus infections after haploidentical and matched unrelated stem cell transplantation. Blood 114 (2009), 4283–4292.
55. 55 Ciceri, F., Bonini, C., Marktel, S., et al. Antitumor effects of HSV-TK-engineered donor lymphocytes after allogeneic stem-cell transplantation. Blood 109 (2007), 4698–4707.
56. 56 Ciceri, F., Bonini, C., Stanghellini, M.T., et al. Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): A non-randomised phase I-II study. Lancet Oncol 10 (2009), 489–500.
57. 57 Sangro, B., Mazzolini, G., Ruiz, M., et al. A phase I clinical trial of thymidine kinase-based gene therapy in advanced hepatocellular carcinoma. Cancer Gene Ther 17 (2010), 837–843.
58. 58 Nasu, Y., Saika, T., Ebara, S., et al. Suicide gene therapy with adenoviral delivery of HSV-tK gene for patients with local recurrence of prostate cancer after hormonal therapy. Mol Ther 15 (2007), 834–840.
59. 59 Colombo, F., Barzon, L., Franchin, E., et al. Combined HSV-TK/IL-2 gene therapy in patients with recurrent glioblastoma multiforme: Biological and clinical results. Cancer Gene Ther 12 (2005), 835–848.
60. 60 Van der Linden, R.R., Haagmans, B.L., Mongiat-Artus, P., et al. Virus specific immune responses after human neoadjuvant adenovirus-mediated suicide gene therapy for prostate cancer. Eur Urol 48 (2005), 153–161.
61. 61 Traversari, C., Marktel, S., Magnani, Z., et al. The potential immunogenicity of the TK suicide gene does not prevent full clinical benefit associated with the use of TK-transduced donor lymphocytes in HSCT for hematologic malignancies. Blood 109 (2007), 4708–4715.
62. 62 Garin, M.I., Garrett, E., Tiberghien, P., et al. Molecular mechanism for ganciclovir resistance in human T lymphocytes transduced with retroviral vectors carrying the herpes simplex virus thymidine kinase gene. Blood 97 (2001), 122–129.
63. 63 Marin, V., Cribioli, E., Philip, B., et al. Comparison of different suicide-gene strategies for the safety improvement of genetically manipulated T cells. Hum Gene Ther Methods 23 (2012), 376–386.
64. 64 Spencer, D.M., Wandless, T.J., Schreiber, S.L., Crabtree, G.R., Controlling signal transduction with synthetic ligands. Science 262 (1993), 1019–1024.
65. 65 Fan, L., Freeman, K.W., Khan, T., Pham, E., Spencer, D.M., Improved artificial death switches based on caspases and FADD. Hum Gene Ther 10 (1999), 2273–2285.
66. 66 Schreiber, S.L., Chemistry and biology of the immunophilins and their immunosuppressive ligands. Science 251 (1991), 283–287.
67. 67 Clipstone, N.A., Crabtree, G.R., Identification of calcineurin as a key signaling enzyme in T-lymphocyte activation. Nature 357 (1992), 695–697.
68. 68 Clackson, T., Yang, W., Rozamus, L.W., et al. Redesigning an FKBP–ligand interface to generate chemical dimerizers with novel specificity. Proc Natl Acad Sci USA 95 (1998), 10437–10442.
69. 69 Iuliucci, J.D., Oliver, S.D., Morley, S., et al. Intravenous safety and pharmacokinetics of a novel dimerizer drug, AP1903, in healthy volunteers. J Clin Pharmacol 41 (2001), 870–879.
70. 70 Straathof, K.C., Pulè, M.A., Yotnda, P., et al. An inducible caspase 9 safety switch for T-cell therapy. Blood 105 (2005), 4247–4254.
71. 71 Tey, S.K., Dotti, G., Rooney, C.M., Heslop, H.E., Brenner, M.K., Inducible caspase 9 suicide gene to improve the safety of allodepleted T cells after haploidentical stem cell transplantation. Biol Blood Marrow Transplant 13 (2007), 913–924.
72. 72 Di Stasi, A., Tey, S.K., Dotti, G., et al. Inducible apoptosis as a safety switch for adoptive cell therapy. N Engl J Med 365 (2011), 1673–1683.
73. 73 Zhou, X., Dotti, G., Krance, R.A., et al. Inducible caspase-9 suicide gene controls adverse effects from alloreplete T cells after haploidentical stem cell transplantation. Blood 125 (2015), 4103–4113.
74. 74 Zhou, X., Naik, S., Dakhova, O., et al. Serial activation of the inducible caspase 9 safety switch after human stem cell transplantation. Mol Ther 24 (2016), 823–831.
75. 75 Solomon, S.R., Tran, T., Carter, C.S., et al. Optimized clinical-scale culture conditions for ex vivo selective depletion of host-reactive donor lymphocytes: A strategy for GvHD prophylaxis in allogeneic PBSC transplantation. Cytotherapy 4 (2002), 395–406.
76. 76 Szabolcs, P., Park, K.D., Marti, L., et al. Superior depletion of alloreactive T cells from peripheral blood stem cell and umbilical cord blood grafts by the combined use of trimetrexate and interleukin-2 immunotoxin. Biol Blood Marrow Transplant 10 (2004), 772–783.
77. 77 Vaclavkova, P., Cao, Y., Wu, L.K., Michalek, J., Vitetta, E.S., A comparison of an anti-CD25 immunotoxin Ontak and anti-CD25 microbeads for their ability to deplete alloreactive T cells in vitro. Bone Marrow Transplant 37 (2006), 559–567.
78. 78 Montagna, D., Yvon, E., Calcaterra, V., et al. Depletion of alloreactive T cells by a specific anti-interleukin-2 receptor p55 chain immunotoxin does not impair in vitro antileukemia and antiviral activity. Blood 93 (1999), 3550–3557.
79. 79 Zhou, X., Di Stasi, A., Tey, S.K., et al. Long-term outcome after haploidentical stem cell transplant and infusion of T cells expressing the inducible caspase 9 safety transgene. Blood 123 (2014), 3895–3905.
80. 80 Chang, E., Liu, H., West, J.A., et al. Clonal dynamics in vivo of virus integration sites of T cells expressing a safety switch. Mol Ther 24 (2016), 736–745.
81. 81 Yagyu, S., Hoyos, V., Del Bufalo, F., Brenner, M.K., Multiple mechanisms determine the sensitivity of human-induced pluripotent stem cells to the inducible caspase-9 safety switch. Mol Ther, 3, 2016, 16003.
82. 82 Barese, C.N., Felizardo, T.C., Sellers, S.E., et al. Regulated apoptosis of genetically modified hematopoietic stem and progenitor cells via an inducible caspase-9 suicide gene in rhesus macaques. Stem Cells 33 (2015), 91–100.